Clinical Trial Update: A Clinical Study Evaluating LY-M001 Injection in the Treatment of Adult Patients With Type I Gaucher Disease [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical study evaluating LY-M001 injection in adults with Gaucher disease type 1 is currently recruiting. The sponsor is Lingyi Biotech Co., Ltd.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gaucher Disease Type

Drugs mentioned

• LY-M001 (LY-M001)

Snippet

Sponsor: Lingyi Biotech Co., Ltd. | Conditions: Gaucher Disease Type 1 | Phase 1, Phase 2 | Status: RECRUITING